viewCytoDyn Inc.

Full interview: CytoDyn files modified protocol for Leronlimab trial battling respiratory complications as a result of contracting Coronavirus

CytoDyn (OTCQB: CYDY) President and CEO Nader Pourhassan joined Steve Darling from Proactive Vancouver to discuss the company filing a modified protocol of their Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients with Coronavirus. 

Pourhassan telling Proactive that new protocol is for 75 planned patients in up to 10 centres in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.


Quick facts: CytoDyn Inc.

Price: 4.73 USD

Market: OTCQB
Market Cap: $2.46 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



CytoDyn continues to works on licensing deals as FDA continues its review on...

CytoDyn (OTCQB: CYDY) President and Chief Executive Officer Nader Pourhassan joined Steve Darling from Proactive to discuss a number of issues including the very latest on their clinical trials for a COVID-19 treatment. Pourhassan also told Proactive that they are in discussions with numerous...

on 5/6/20

2 min read